Morphologic features of human chorionic gonadotropin- or alpha-fetoprotein-producing germ cell tumors of the central nervous system: histological heterogeneity and surgical meaning.
Our study of germ cell tumors (GCT) of the central nervous system (CNS) investigated the relationship between tumor histology and patient serum titers of human chorionic gonadotropin (HGC) and alpha-fetoprotein (AFP). Thirty-five patients were enrolled. Their serum titers of HCG (mlU/ml) and/or AFP (ng/ml) before initial treatment were available, as were tumor specimens obtained before the administration of adjuvant therapy. They were divided into three groups, depending on whether HCG alone (group H), AFP alone (group A), or both HCG and AFP (group HA) were detected. Each group was subdivided into three groups: patients in group I had H, A, and/or HA titers below 9.9; patients in group II/III had titers from 10.0 to 999; and those in group IV had titers of 1000 or more. Serial sections of tissue specimens were repeatedly stained, mainly with hematoxylin and eosin (H-E) stain, HCG immunostain, and AFP immunostain. There were seven patients in the H-I group and five in H-II/III. Of these 12 patients, 11 had germinomas (G) and one had an embryonal carcinoma (EC). Five patients were included in group A: one was classified as A-II/III and had a germinoma, and the remaining four patients were in A-IV and had yolk sac tumors (YST) or mixed GCT consisting mainly of YST or EC (MXGCT-YST, EC). The HA group consisted of 18 patients. Three were classified as HA-I and had germinomas; nine HA-II/III patients had T or MXGCT-T; and six HA-IV patients had choriocarcinoma (CC), YST, MXGCT-CC, or MXGCT-YST. Throughout the study, the situations for the elevated serum titers could be elucidated in only four cases (three in group A-IV and one in group HA-IV). These results led to the conclusion that serologic evaluation is superior to morphologic evaluation in diagnosing marker-producing GCTs. From a diagnostic perspective, the role of surgery is to verify the HCG- and AFP-immunonegative tissue in patients with G, T, and EC.
Sugiyama
K
K
Department of Neurosurgery, Hiroshima University Medical Hospital, Japan. brain@hiroshima-u.ac.jp
Arita
K
K
Tominaga
A
A
Hanaya
R
R
Taniguchi
E
E
Okamura
T
T
Itoh
Y
Y
Yamasaki
F
F
Kurisu
K
K
D000293:Adolescent; D000328:Adult; D001479:Basal Ganglia / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D018236:Carcinoma, Embryonal / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D002551:Cerebral Ventricle Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D002822:Choriocarcinoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D006063:Chorionic Gonadotropin / Q000032:analysis*; D003131:Combined Modality Therapy; D018240:Endodermal Sinus Tumor / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D005260:Female; D018237:Germinoma / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000032:analysis*; D009373:Neoplasms, Germ Cell and Embryonal / Q000145:classification / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D009419:Nerve Tissue Proteins / Q000032:analysis*; D010870:Pineal Gland; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D013194:Staining and Labeling; D000509:alpha-Fetoproteins / Q000032:analysis*
D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D000509:alpha-Fetoproteins